Indo Amines reports ₹79.33 crore PAT, recommends 10% dividend for FY26
- Consolidated revenue rose to ₹1,159.66 crore in FY26 from ₹1,078.68 crore in FY25
- Profit After Tax increased 41.9% YoY to ₹79.33 crore
- Board recommended a 10% final dividend of ₹0.50 per share
- Standalone EBITDA margin stood at 13.13% with PAT margin at 7.05%
- New product line "Morpholine and Derivatives" launched at Dhule plant

*this image is generated using AI for illustrative purposes only.
Indo Amines reported consolidated revenue of ₹1,159.66 crore for FY26, up from ₹1,078.68 crore in the previous year. Profit After Tax (PAT) increased to ₹79.33 crore, compared with ₹55.90 crore in FY25.
The company’s 33rd Annual General Meeting (AGM), held on September 24, 2026, via video conferencing, approved the adoption of standalone and consolidated audited financial statements. Shareholders also ratified the recommendation of a 10% final dividend (₹0.50 per equity share of face value ₹5).
Financial Performance Overview
During the meeting, Chairman Pradeep Thakur highlighted the company’s resilience amid global raw material volatility and supply chain disruptions. The financial results reflect growth across both top and bottom lines.
| Metric | FY26 | FY25 | Change |
|---|---|---|---|
| Consolidated Revenue | ₹1,159.66 crore | ₹1,078.68 crore | +7.5% |
| Profit Before Tax | ₹106.11 crore | ₹76.95 crore | +37.9% |
| Profit After Tax | ₹79.33 crore | ₹55.90 crore | +41.9% |
On a standalone basis, Indo Amines reported revenue growth of 5.81%, with an EBITDA margin of 13.13% and a PAT margin of 7.05%.
What the Numbers Show
The disparity between revenue growth (7.5%) and Profit After Tax growth (41.9%) indicates significant operating leverage or margin expansion during FY26. While top-line growth was moderate, the bottom-line expansion suggests improved cost efficiency or better realization rates, as evidenced by the standalone EBITDA margin holding at 13.13%.
Strategic Developments and Governance
Managing Director Vijay Palkar noted the launch of "Morpholine and Derivatives" at the Dhule plant, expanding the product portfolio for domestic and international markets. The company plans to pursue strategic acquisitions and backward integration to diversify into value-added chemistries.
Key governance updates from the AGM include:
- Re-appointment of Saji Jose and Tejaswini Dalvi as directors retiring by rotation.
- Appointment of Rahul Chitnis as Independent Director for a one-year term.
- Ratification of remuneration for the Cost Auditor for FY27.
The meeting concluded with e-voting results to be announced within two working days. No registered shareholders spoke during the session.
Historical Stock Returns for Indo Amines
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -1.89% | +9.28% | +9.91% | +63.76% | -4.72% | +18.64% |
How will the margin expansion observed in FY26 be sustained in FY27 given the ongoing global raw material volatility?
What specific capital allocation plans are in place for the announced strategic acquisitions and backward integration initiatives?
What is the projected contribution of the newly launched Morpholine and Derivatives product line to consolidated revenue in the coming fiscal year?
































